A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: a UNICANCER French Sarcoma Group study (LMS03 study)
Nom du journal : Eur J Cancer
Année : 2020
Volume : 125
Page de départ : 31
Page de fin : 37